Related references
Note: Only part of the references are listed.Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017
Audrey D. Zhang et al.
JAMA NETWORK OPEN (2020)
Impact of physicians' participation in non-interventional post-marketing studies on their prescription habits: A retrospective 2-armed cohort study in Germany
Cora Koch et al.
PLOS MEDICINE (2020)
Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis
Joshua D. Wallach et al.
BMC MEDICINE (2019)
Pharmaceutical Drugs of Uncertain Value, Lifecycle Regulation at the US Food and Drug Administration, and Institutional Incumbency
Matthew Herder
MILBANK QUARTERLY (2019)
Timeliness of Postmarket Studies for New Pharmaceuticals Approved Between 2009 and 2012: a Cross-Sectional Analysis
Joshua D. Wallach et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2019)
Assessment of Pregabalin Postapproval Trials and the Suggestion of Efficacy for New Indications A Systematic Review
Carole A. Federico et al.
JAMA INTERNAL MEDICINE (2019)
Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments
Joshua J. Skydel et al.
JAMA NETWORK OPEN (2019)
Post-marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross-sectional study
Jean-David Zeitoun et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Factors Associated With Postmarketing Research for Approved Indications for Novel Medicines Approved by Both the FDA and EMA Between 2005 and 2010: A Multivariable Analysis
Jean-David Zeitoun et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements
Joshua D. Wallach et al.
CLINICAL TRIALS (2018)
The US Food and Drug Administration's expedited approval programs: Addressing premarket flexibility with enhanced postmarket evidence generation
Joshua D. Wallach et al.
CLINICAL TRIALS (2018)
Clinical Trial Evidence Supporting FDA Approval of Drugs Granted Breakthrough Therapy Designation
Jeremy Puthumana et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis
Joshua D. Wallach et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis
Joshua D. Wallach et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Timing and Characteristics of Cumulative Evidence Available on Novel Therapeutic Agents Receiving Food and Drug Administration Accelerated Approval
Huseyin Naci et al.
MILBANK QUARTERLY (2017)
The Fate of FDA Postapproval Studies
Steven Woloshin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Postmarketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional study
Jean-David Zeitoun et al.
BMJ OPEN (2017)
Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review
Alison M. Pease et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review
Alison M. Pease et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization Timelines
Lawrence Liberti et al.
FRONTIERS IN PHARMACOLOGY (2017)
The Trade-off Between Speed and Safety in Drug Approvals
Anupam B. Jena et al.
JAMA ONCOLOGY (2017)
FDA Policy and Cardiovascular Medicine
Joseph S. Ross et al.
CIRCULATION (2015)
Electronic Health Data for Postmarket Surveillance: A Vision Not Realized
Thomas J. Moore et al.
DRUG SAFETY (2015)
Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study
Aaron S. Kesselheim et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study
Aaron S. Kesselheim et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012
Nicholas S. Downing et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Innovating by Developing New Uses of Already-Approved Drugs: Trends in the Marketing Approval of Supplemental Indications
Joseph A. DiMasi
CLINICAL THERAPEUTICS (2013)
The Food and Drug Administration Amendments Act and Postmarketing Commitments
Kevin Fain et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Pharmacovigilance: An Active Surveillance System to Proactively Identify Risks for Adverse Events
Christopher Moses et al.
POPULATION HEALTH MANAGEMENT (2013)
Monitoring the Safety of Medicines Used Off-Label
G. J. Dal Pan
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
A Lifecycle Approach to the Evaluation of FDA Approval Methods and Regulatory Actions Opportunities Provided by a New IOM Report
Bruce M. Psaty et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
The US Food and Drug Administration's Sentinel Initiative: Expanding the horizons of medical product safety
Melissa A. Robb et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2012)
2010 FDA drug approvals
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2011)
2009 FDA drug approvals
Bethan Hughes
NATURE REVIEWS DRUG DISCOVERY (2010)
Share Paper
